<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Spear Bio — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Diagnostics / Neuro</span>
    <h1>137. Spear Bio</h1>
    <p class="meta">FDA Breakthrough Device for Alzheimer's pTau 217 Blood Test</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Spear Bio</strong></p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Tell me more about this company's origin story...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Peng Yin & Feng Xuan</strong></p><p>Wyss Institute</p><p>Dr. Yin is a leader in DNA nanotechnology; Spear Bio applies ultra-sensitive detection to Alzheimer's biomarkers</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Research the founder's background and credentials...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>3. Product Overview</h3><p>Spear Bio develops ultra-sensitive blood tests for Alzheimer's disease detection, with FDA Breakthrough Device Designation for their pTau 217 assay. Phosphorylated tau 217 is emerging as the most accurate blood biomarker for Alzheimer's pathology, and Spear Bio's proprietary detection technology enables measurement at the extremely low concentrations present in blood. This could transform Alzheimer's diagnosis from expensive PET scans and invasive spinal taps to a simple blood draw.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What competitors does this product face?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Seed Prime — Oversubscribed</strong> — Strong investor interest driven by FDA Breakthrough Device designation and Alzheimer's blood test opportunity.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What's the typical next funding milestone?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute portfolio and coverage of Alzheimer's blood biomarker advances.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Find more recent news about this company...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>FDA Breakthrough Device:</strong> Expedited regulatory pathway signals clinical importance.</li><li><strong>Right biomarker:</strong> pTau 217 emerging as gold standard blood marker for Alzheimer's.</li><li><strong>Massive market:</strong> 6+ million Americans with Alzheimer's; millions more at risk need screening.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Validate these strengths with market data...">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Competitive race:</strong> Roche, C2N, and others are also pursuing pTau 217 blood tests.</li><li><strong>Regulatory unknowns:</strong> First blood-based Alzheimer's diagnostics still navigating approval.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What other risks should I consider?">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>How does your assay sensitivity compare to Roche's Elecsys and C2N's PrecivityAD?</li><li>What is your FDA regulatory timeline with Breakthrough Device designation?</li><li>Are you targeting clinical labs, point-of-care, or both for deployment?</li><li>How does the new Alzheimer's drug landscape (Leqembi, donanemab) impact demand for your test?</li><li>What is your pricing strategy relative to existing Alzheimer's diagnostics?</li></ol>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Generate additional due diligence questions...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section email-draft">
    <h3>8. Draft Outreach Email</h3>
    <div class="email-box">
      <p><strong>Subject:</strong> Harvard Undergraduate Capital Partners — Alzheimer's Diagnostics Breakthrough</p>
      <p>Dear Spear Bio Team,</p>
      <p>I'm reaching out from <strong>Harvard Undergraduate Capital Partners (HUCP)</strong>, a student-run investment group at Harvard focused on early-stage ventures led by Harvard-affiliated founders.</p>
      <p>We've been following Spear Bio's development of ultra-sensitive Alzheimer's blood tests with great interest. The FDA Breakthrough Device designation for your pTau 217 assay is a significant milestone, and the potential to transform Alzheimer's diagnosis from invasive procedures to a simple blood test could impact millions of patients. Dr. Yin's pioneering work at the Wyss Institute provides exceptional scientific foundation.</p>
      <p>Despite your oversubscribed seed round, we would be honored to learn more about Spear Bio's journey. Would anyone on the team be open to a brief conversation with students from your Harvard community?</p>
      <p>Thank you for your consideration.</p>
      <p>Best,<br>[Your Name]<br>Harvard Undergraduate Capital Partners</p>
    </div>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Personalize this email with more specific details...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
<script src="script.js?v=4"></script>
</body>
</html>
